AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10668944 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose oral ofloxacin
Number of subjects: 110
Study 10668944 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose oral trimethoprim-sulfamethoxazole
Number of subjects: 110
Study 10668944 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 110
Study 8537804 — intervention group
Group type: EXPERIMENTAL
Intervention: OCPs with a BSE prompt
Number of subjects: 907
Study 8537804 — intervention group
Group type: COMPARATOR
Intervention: Regularly packaged OCPs (without BSE prompt)
Number of subjects: 907
Study 1898998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous flecainide (2 mg/kg, maximum dose 150 mg) with digoxin (500 micrograms)
Number of subjects: 102
Study 1898998 — intervention group
Group type: COMPARATOR
Intervention: Placebo with digoxin (500 micrograms)
Number of subjects: 102
Study 7202238 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexedrine 2.5 mg twice daily
Number of subjects: 10
Study 7202238 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexedrine 5 or 10 mg twice daily
Number of subjects: 10
Study 3887910 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management
Number of subjects: 105
Study 3887910 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual support
Number of subjects: 105
Study 3887910 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 105
Study 29205809 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft silicone-coated wound contact layer (Mepitel One)
Number of subjects: 121
Study 29205809 — intervention group
Group type: COMPARATOR
Intervention: Lipidocolloid wound contact layer (UrgoTul)
Number of subjects: 121
Study 27030648 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood purification group (BP) received continuous venous‐venous hemodiafiltration in addition to conventional treatment.
Number of subjects: 41
Study 24886225 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealthcare intervention
Number of subjects: 1200
Study 24886225 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 1200
Study 22236918 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-monthly home visits for questionnaire-based TB screening plus record surveillance of TB registers, hospital admission and X-ray lists at health facilities for TB suspects and cases (Group 1)
Number of subjects: 4786
Study 22236918 — intervention group
Group type: COMPARATOR
Intervention: Record surveillance only (Group 2)
Number of subjects: 4786
Study 22236918 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 4786
Study 22236918 — intervention group
Group type: COMPARATOR
Intervention: Group 2
Number of subjects: 4786
Study 19415341 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg/day American ginseng
Number of subjects: 290
Study 19415341 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg/day American ginseng
Number of subjects: 290
Study 19415341 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 mg/day American ginseng
Number of subjects: 290
Study 19415341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 18560878 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) for 6 weeks, pressure-threshold IMT
Number of subjects: 22
Study 18560878 — intervention group
Group type: COMPARATOR
Intervention: Control group, no IMT
Number of subjects: 22
Study 15724142 — intervention group
Group type: EXPERIMENTAL
Intervention: DAT1 gene influence on caudate volume
Number of subjects: 0
Study 15724142 — intervention group
Group type: EXPERIMENTAL
Intervention: DRD4 gene influence on prefrontal gray matter volume
Number of subjects: 0
Study 14601350 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires disclosed and scored by GPs
Number of subjects: 1785
Study 14601350 — intervention group
Group type: COMPARATOR
Intervention: Questionnaires blinded
Number of subjects: 1785
Study 10645192 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual energy X-ray absorptiometry (DXA) of the calcaneus
Number of subjects: 55
Study 8762416 — intervention group
Group type: EXPERIMENTAL
Intervention: Buqi Qiangxin decoction (BQQXD)
Number of subjects: 52
Study 8762416 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 52
Study 1707795 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalogram (EEG)
Number of subjects: 90
Study 1707795 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potentials (SEPs)
Number of subjects: 90
Study 1707795 — intervention group
Group type: COMPARATOR
Intervention: Comparison of EEG and SEPs
Number of subjects: 90
Study 6619669 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone leg length-differential test measured by three experienced chiropractic clinicians
Number of subjects: 40
Study 30765407 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical spinal decompression
Number of subjects: 160
Study 30765407 — intervention group
Group type: COMPARATOR
Intervention: Placebo surgical intervention
Number of subjects: 160
Study 29957099 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried apple
Number of subjects: 21
Study 29957099 — intervention group
Group type: COMPARATOR
Intervention: Muffins
Number of subjects: 21
Study 27482750 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (Castrate)
Number of subjects: 56
Study 27482750 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 g testosterone gel (Low T/E)
Number of subjects: 56
Study 27482750 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g testosterone gel (Normal T/E)
Number of subjects: 56
Study 27482750 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g testosterone gel with letrozole (Normal T/Low E)
Number of subjects: 56
Study 25274220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (UGFS)
Number of subjects: 0
Study 25274220 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 0
Study 25274220 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study 23235130 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily chewing gum containing xylitol (A)
Number of subjects: 173
Study 23235130 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine/xylitol/sorbitol (B)
Number of subjects: 173
Study 23235130 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride/xylitol/sorbitol (C)
Number of subjects: 173
Study 23235130 — intervention group
Group type: COMPARATOR
Intervention: Control group (D) - children of mothers with low counts of salivary mutans streptococci
Number of subjects: 173
Study 20202160 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% thiazone and 5‐min ultrasound (0.25%T/SP)
Number of subjects: 0
Study 20202160 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 400 (PEG400)
Number of subjects: 0
Study 20202160 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% thiazone (0.25%T)
Number of subjects: 0
Study 20202160 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 0
Study 18818563 — intervention group
Group type: EXPERIMENTAL
Intervention: Light needling acupuncture on point LI4 on both hands for approximately 20 seconds on four occasions
Number of subjects: 40
Study 18818563 — intervention group
Group type: COMPARATOR
Intervention: Control group (same care except needling)
Number of subjects: 40
Study 18818563 — intervention group
Group type: EXPERIMENTAL
Intervention: Light needling acupuncture
Number of subjects: 40
Study 15768203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 0
Study 12467070 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal tretinoin administered three times weekly
Number of subjects: 76
Study 12467070 — intervention group
Group type: COMPARATOR
Intervention: Liposomal tretinoin administered once weekly
Number of subjects: 76
Study 10840537 — intervention group
Group type: EXPERIMENTAL
Intervention: aprotinin (high-dose-scheme)
Number of subjects: 60
Study 10840537 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid (2 g/h)
Number of subjects: 60
Study 10840537 — intervention group
Group type: COMPARATOR
Intervention: no antifibrinolytic therapy (control group)
Number of subjects: 60
Study 8690552 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert panel assessment of gain in life expectancy
Number of subjects: 0
Study 8690552 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert panel assessment of gain in quality of life
Number of subjects: 0
Study 1854445 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride/triclosan/copolymer dentifrice (0.3% triclosan, 2.0% copolymer, 0.243% sodium fluoride/silica base)
Number of subjects: 70
Study 1854445 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice (0.243% sodium fluoride in silica base)
Number of subjects: 70
Study 6662766 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g fructose (F)
Number of subjects: 8
Study 6662766 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g glucose (G)
Number of subjects: 8
Study 6662766 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 8
Study 31764468 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous-intensity physical activity (MVPA) 150-300 min/week
Number of subjects: 346
Study 31764468 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous-intensity physical activity (MVPA) >300 min/week
Number of subjects: 346
Study 31764468 — intervention group
Group type: COMPARATOR
Intervention: Moderate to vigorous-intensity physical activity (MVPA) <150 min/week
Number of subjects: 346
Study 29394188 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly low‐to‐moderate intensity resistance training
Number of subjects: 134
Study 29394188 — intervention group
Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 134
Study 29394188 — intervention group
Group type: COMPARATOR
Intervention: Bimonthly pregnancy education classes
Number of subjects: 134
Study 26206077 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day aprepitant
Number of subjects: 93
Study 26206077 — intervention group
Group type: COMPARATOR
Intervention: Single administration of fosaprepitant meglumine
Number of subjects: 93
Study 24990067 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine infiltration (75 mg/30 cc)
Number of subjects: 46
Study 24990067 — intervention group
Group type: COMPARATOR
Intervention: Saline infiltration (30 cc)
Number of subjects: 46
Study 24990067 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 22209796 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency TENS (HF-TENS)
Number of subjects: 27
Study 22209796 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS (P-TENS)
Number of subjects: 27
Study 20560029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of CD133(+) bone marrow stem cells
Number of subjects: 14
Study 20560029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 17654129 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (Seretide) 50/250 microg twice daily (SFC)
Number of subjects: 362
Study 17654129 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (Flixotide) 250 microg twice daily (FP)
Number of subjects: 362
Study 15857224 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-wave bolus (100% of insulin given immediately)
Number of subjects: 24
Study 15857224 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-h dual-wave bolus (50% of insulin given immediately and 50% given over a 4-h period)
Number of subjects: 24
Study 15857224 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-h dual-wave bolus (50% of insulin given immediately and 50% given over a 8-h period)
Number of subjects: 24
Study 12145009 — intervention group
Group type: EXPERIMENTAL
Intervention: High-isoflavone diet (56 mg isoflavones/d)
Number of subjects: 22
Study 12145009 — intervention group
Group type: COMPARATOR
Intervention: Low-isoflavone diet (2 mg isoflavones/d)
Number of subjects: 22
Study 10442277 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 124
Study 10442277 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 124
Study 8568190 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-insoluble carob fraction (FIC, 1970 mg every 2 hours for 48 hours)
Number of subjects: 164
Study 8568190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 2203481 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone administered from day 0 through 35 along with methotrexate/cyclosporine
Number of subjects: 147
Study 2203481 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate/cyclosporine without prednisone
Number of subjects: 147
Study 2203481 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate/cyclosporine along with 'late' prednisone starting on day 15
Number of subjects: 147
Study 1266576 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa + carbidopa (Sinemet)
Number of subjects: 92
Study 1266576 — intervention group
Group type: COMPARATOR
Intervention: levodopa + benserazide (Madopar)
Number of subjects: 92
Study 31692016 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg, 4 times daily for 4 days)
Number of subjects: 301
Study 31692016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 31738716 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-hour BBN simulation-based training (training group, n = 37)
Number of subjects: 68
Study 31738716 — intervention group
Group type: COMPARATOR
Intervention: 160-hour ED clinical rotation without a formal BBN curriculum (control group, n = 31)
Number of subjects: 68
Study 28236512 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery coach for parents (experimental group)
Number of subjects: 3440
Study 28236512 — intervention group
Group type: COMPARATOR
Intervention: Services as usual (control group)
Number of subjects: 3440
Study 25333793 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of a culturally tailored video about HPV, cervical cancer, Self‐HPV and its relevancy as a screening test.
Number of subjects: 302
Study 25333793 — intervention group
Group type: COMPARATOR
Intervention: Standard information (control group) including explanations about what the test detects (HPV), the link between HPV and cervical cancer and how to perform HPV self‐sampling.
Number of subjects: 302
Study 24356755 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Sedation (MS) using TCI-delivered propofol and remifentanil
Number of subjects: 92
Study 24356755 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA) using TCI-delivered propofol and remifentanil with HFJV
Number of subjects: 92
Study 20593742 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral galantamine
Number of subjects: 84
Study 20593742 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine transdermal patch
Number of subjects: 84
Study 18287179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin + vitamin E + homocysteine-lowering B-vitamin therapy
Number of subjects: 93
Study 18287179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 17194264 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS treatment
Number of subjects: 33
Study 17194264 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 33
Study 17194264 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS treatment with stimulation intensity below 90% of motor threshold
Number of subjects: 33
Study 17194264 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS treatment with new medication starting within 7 days before to 7 days after start of TMS
Number of subjects: 33
Study 14568368 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation program (n=15)
Number of subjects: 23
Study 14568368 — intervention group
Group type: COMPARATOR
Intervention: Educational advice (Control group, n=8)
Number of subjects: 23
Study 11069333 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal first/oral second group (10 nasal intubations followed by 10 oral intubations)
Number of subjects: 30
Study 11069333 — intervention group
Group type: COMPARATOR
Intervention: Oral first/nasal second group (10 oral intubations followed by 10 nasal intubations)
Number of subjects: 30
Study 11069333 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal first/oral second group
Number of subjects: 30
Study 11069333 — intervention group
Group type: COMPARATOR
Intervention: Oral first/nasal second group
Number of subjects: 30
Study 9118715 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled and systemic corticosteroids
Number of subjects: 0
Study 9118715 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid therapy
Number of subjects: 0
Study 7917772 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral doses of lazabemide (100‐300 mg)
Number of subjects: 75
Study 7917772 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple oral doses of lazabemide (100‐350 mg 12 hourly for 7 days)
Number of subjects: 75
Study 7917772 — intervention group
Group type: EXPERIMENTAL
Intervention: Single and multiple dosing of lazabemide
Number of subjects: 75
Study 3288016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergot alkaloid (co-dergocrine mesylate) 3 x 2 mg/day for 8 weeks
Number of subjects: 90
Study 3288016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (slow-release formulation) 3 x 400 mg/day for 8 weeks
Number of subjects: 90
Study 3288016 — intervention group
Group type: COMPARATOR
Intervention: Standard basic therapy (control group)
Number of subjects: 90
Study 31379380 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT), 30 weekly sessions
Number of subjects: 58
Study 31379380 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 58
Study 28744115 — intervention group
Group type: EXPERIMENTAL
Intervention: GB 12.5 μg BID
Number of subjects: 38
Study 28744115 — intervention group
Group type: EXPERIMENTAL
Intervention: GB 25 μg BID
Number of subjects: 38
Study 28744115 — intervention group
Group type: EXPERIMENTAL
Intervention: GB 50 μg BID
Number of subjects: 38
Study 28744115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 28744115 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18 μg once daily
Number of subjects: 38
Study 28744115 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 μg
Number of subjects: 38
Study 28665378 — intervention group
Group type: EXPERIMENTAL
Intervention: General magnetic therapy in addition to initial therapy (medication, therapeutic physical exercises, aquatic therapy)
Number of subjects: 73
Study 28665378 — intervention group
Group type: COMPARATOR
Intervention: Control group (initial therapy only)
Number of subjects: 73
Study 28665378 — intervention group
Group type: EXPERIMENTAL
Intervention: General magnetic therapy
Number of subjects: 73
Study 24070098 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART score calculation to guide clinical decision
Number of subjects: 6600
Study 21378715 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gums with stevioside (1.25% and 2.5%)
Number of subjects: 126
Study 21378715 — intervention group
Group type: COMPARATOR
Intervention: Placebo (a basis without additives)
Number of subjects: 126
Study 21378715 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing sweets R.O.C.S. and other gums with sugar substitutes (xylitol, sorbitol)
Number of subjects: 126
Study 19675744 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5‐FU at a dose of 1250 mg/qm(2) twice a day for two weeks, then paused for a week, restarted; oral thalidomide at a maximum dose of 400 mg/d for three months
Number of subjects: 12
Study 17170202 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic training (60% O2)
Number of subjects: 9
Study 17170202 — intervention group
Group type: COMPARATOR
Intervention: Normoxic training
Number of subjects: 9
Study 15709454 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol 1.25 mg
Number of subjects: 362
Study 15709454 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment groups (Levalbuterol and Racemic Albuterol)
Number of subjects: 362
Study 15709454 — intervention group
Group type: COMPARATOR
Intervention: Racemic Albuterol
Number of subjects: 362
Study 15709454 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol
Number of subjects: 362
Study 11470011 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist therapy
Number of subjects: 0
Study 11470011 — intervention group
Group type: COMPARATOR
Intervention: Diuretic and beta-blocker therapy
Number of subjects: 0
Study 8635924 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral feeding with a nasogastric tube
Number of subjects: 20
Study 8635924 — intervention group
Group type: COMPARATOR
Intervention: Oral feeding without a nasogastric tube
Number of subjects: 20
Study 8635924 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of nasogastric tube
Number of subjects: 20
Study 8635924 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition from tube feedings to oral feedings
Number of subjects: 20
Study 8635924 — intervention group
Group type: EXPERIMENTAL
Intervention: Desaturation events
Number of subjects: 20
Study 1617923 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin (300 mg once daily)
Number of subjects: 76
Study 1617923 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (200 mg once daily)
Number of subjects: 76
Study 4051323 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 ppm O3 exposure
Number of subjects: 23
Study 4051323 — intervention group
Group type: COMPARATOR
Intervention: Clean air exposure
Number of subjects: 23
Study 29400630 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity buddy program
Number of subjects: 49
Study 29400630 — intervention group
Group type: COMPARATOR
Intervention: Inactive buddies
Number of subjects: 49
Study 29400630 — intervention group
Group type: EXPERIMENTAL
Intervention: Active buddies
Number of subjects: 49
Study 30864756 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed (62.34% of cases)
Number of subjects: 908
Study 30864756 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician practices
Number of subjects: 908